Alector Inc.
Alector, Inc. is a late‑stage clinical biotech developing neurodegeneration therapies. Its lead candidates Latozinemab (AL001) and AL101 are in Phase 3/2 for frontotemporal dementia, Alzheimer’s, and Parkinson’s. Partnering with GSK, it has a broad antibody pipeline.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Hospitals and Health Care
- Industry: Medical Practices
- Employees: 156
- HQ: South San Francisco
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.